SCHEMBL718346

SCHEMBL718346

COc1cccc(-n2cc(C)c(C=O)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.46
ADORA3 P0DMS8 2/20 0.45
ADORA1 P30542 2/20 0.45
LMNA P02545 3/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
NLRP3 Q96P20 1/20 0.44
ADORA2A P29274 1/20 0.43
CYP1A2 P05177 1/20 0.43
MGLL Q99685 1/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
BRAF P15056 1/20 0.41
MAPK14 Q16539 1/20 0.41
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
BCHE P06276 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717454 0.84 MEN1 (0.50) ADORA3ADORA1KMT2AMEN1NLRP3
SCHEMBL718967 0.80 MEN1 (0.53) NOTUMADORA3ADORA1LMNAKMT2A
SCHEMBL719924 0.75 HSD17B10 (0.54) NOTUMADORA3ADORA1LMNAADORA2A
SCHEMBL719895 0.74 MEN1 (0.50) NOTUMADORA3ADORA1LMNAKMT2A
SCHEMBL717894 0.74 MEN1 (0.50) NOTUMADORA3ADORA1LMNAKMT2A
SCHEMBL28504786 0.74 NOTUM (0.51) NOTUMADORA3ADORA1LMNAKMT2A
SCHEMBL2557532 0.73 MEN1 (0.52) NOTUMADORA3ADORA1LMNAKMT2A
SCHEMBL720576 0.73 MEN1 (0.49) NOTUMADORA3ADORA1LMNAKMT2A
SCHEMBL719885 0.72 ALDH1A1 (0.46) ADORA3ADORA1KMT2AMEN1ADORA2A
SCHEMBL718714 0.72 NPC1 (0.56) LMNACYP1A2HSD17B10SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NOTUM 1954/4885ADORA3 2906/4885ADORA1 2915/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NOTUM 1954/4885ADORA3 2906/4885ADORA1 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.